Ipamorelin UK legal status
Ipamorelin is a selective growth-hormone secretagogue commonly stacked with CJC-1295 in the consumer peptide market. It is not a licensed UK medicine and WADA treats it as prohibited under S2.
Current UK regulatory framing
Ipamorelin is a pentapeptide growth-hormone secretagogue (GHS), acting at the ghrelin / GHS-R1a receptor to release endogenous GH from the pituitary. It is not a UK-licensed medicine — ipamorelin’s pharmaceutical development was discontinued after early-phase trials for post-operative ileus, and it has not been authorised in any major regulatory jurisdiction for human use.
Selling ipamorelin as a medicine, with medicinal claims, or with accompanying dosing guidance is supplying an unauthorised medicinal product. The familiar “research only” framing does not displace that analysis.
The selectivity argument
Ipamorelin is often marketed as a “cleaner” GHS because it releases GH without meaningfully raising cortisol or prolactin (unlike GHRP-6 or hexarelin). That pharmacological selectivity is real. It does not:
- Make ipamorelin a licensed UK medicine.
- Remove the supply offence for selling it.
- Resolve the long-term-safety question for repeated GH-axis stimulation in non-deficient adults.
- Affect WADA strict liability.
Sport — WADA S2
GH secretagogues fall under S2 of the WADA Prohibited List. Prohibited at all times. Athletes face strict-liability sanctions. Detection of ipamorelin and related GHS via metabolite testing has improved substantially.
The CJC + ipamorelin stack
The most-marketed pairing combines ipamorelin’s GH pulse with the sustained CJC-1295 baseline lift. The stack is marketed as a “safer HGH alternative”. Neither component is licensed in the UK; both are S2; the combination has no UK marketing authorisation and no human RCT evidence for marketed outcomes. See CJC-1295 UK legal status for the full picture.
What this means in practice
For sellers
Ipamorelin sold with reconstitution guidance, dosing tables, and anti-ageing or body-composition claims is presented as a medicine. MHRA and ASA jurisdiction follows.
For clinics
A “peptide therapy clinic” offering ipamorelin injections for anti-ageing or recovery is supplying an unlicensed compound for a human-health purpose. The clinical-governance question (“what licensed medicine is the prescriber taking responsibility for?”) does not have an answer here.
For athletes
Don’t. Strict-liability risk is direct and current testing methodology detects ipamorelin metabolites.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Ipamorelin — the safest GH peptide”
‘Safest of the unlicensed substances’ is still unlicensed-substance use. Comparative-safety language doesn't translate to a regulatory or legal protection.
“Stack with CJC-1295 for real GH gains”
Both unlicensed; both S2; combination unsupported in human RCTs.
“Peptide therapy at our anti-ageing clinic — ipamorelin protocols”
Clinic offer of unlicensed-substance therapy. CQC and MHRA scrutiny territory.
“Research-grade ipamorelin — perfect for athletes”
Direct WADA S2 exposure. ‘Research-grade’ doesn't change strict liability.
Sources & further reading
- MHRA — gov.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- WADA Prohibited List (S2) — wada-ama.org
- Global DRO — globaldro.com
Frequently asked questions
- Is ipamorelin legal in the UK?
- Ipamorelin is not a licensed UK medicine. Supplying it as a medicine, or with medicinal claims, is unlawful under the Human Medicines Regulations 2012.
- Is ipamorelin prohibited in sport?
- Yes. GH secretagogues including ipamorelin fall under S2 of the WADA Prohibited List. Prohibited at all times. Strict liability applies.
- Is ipamorelin ‘safer’ than other GH peptides?
- Pharmacologically, ipamorelin is selective for GH release without raising cortisol or prolactin meaningfully. That doesn't make it a licensed medicine or remove the unlicensed-substance and anti-doping risks.
- Can a UK clinic prescribe ipamorelin?
- There is no UK licence to prescribe ipamorelin under. A clinic offering ‘peptide therapy’ with ipamorelin is supplying an unlicensed compound for a human-health purpose.
- What's the evidence base?
- Short-term human pharmacokinetic data exists. Long-term clinical-outcome trials in non-deficient adults are lacking. Anti-ageing and body-recomposition claims exceed the evidence base.